IMR Press / FBL / Special Issues / signaling_pathways

Signaling Pathways in Cancers

Submission deadline: 15 December 2022
Special Issue Editors
  • Kelly Avery-Kiejda, PhD
    School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, Australia
    Interests: breast cancer; metastasis; p53; chemoresistance; miRNAs; epigenetics
  • Kira Groen, PhD
    School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, Australia
    Interests: breast cancer; melanoma; p53; miRNAs; epigenetics; extracellular vesicles
Special Issue Information

Dear Colleagues,

This Special Issue will feature a series of contributions addressing the role of signaling pathways in cancer. Signaling pathways in cancer cells are recognized for their vital role in controlling important cellular processes including cell cycle progression, apoptosis, DNA repair, cell metabolism, and angiogenesis. Thus, these biological mechanisms are intricately linked to cancer initiation, growth, and metastatic tumor behavior. Several oncogenes (e.g., MYC, RAS, BRAF and KIT) and tumor suppressor genes (e.g., TP53, BRCA1 and PTEN) are known to be commonly mutated in cancer, and drive key molecular networks required for either cancer propagation or suppression. With the advent of comprehensive omic approaches, our understanding of the molecular networks deregulated in cancer has grown considerably over the last few years. However, these discoveries have made it abundantly clear how heterogenous these networks are between different cancer types, between individuals with the same cancer type, between different tumors within the same patient following cancer dissemination, and even within the same tumor when different regions are sampled. More recently, the heterogeneity and complexity of cancer has been further unraveled using single cell techniques as these approaches afford crucial insight into the dysfunction of molecular networks in distinct cell types within a tumor. Increasing our understanding of such critical networks has great promise in highlighting novel therapeutic strategies for cancer patients, especially for those with advanced disease.

In this Special Issue, we welcome original research and review articles that explore signaling pathways that are disrupted in cancer, and in particular, metastatic disease. We invite submissions that provide novel insight into biomarkers and those that advance our understanding of the biological and molecular consequences of these alterations.

Dr. Kelly Avery-Kiejda and Dr. Kira Groen

Guest Editors

Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (1 Paper)
Back to top